Clinical Trials Logo

PEG-rhG-CSF clinical trials

View clinical trials related to PEG-rhG-CSF.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT04518800 Not yet recruiting - Pancreatic Cancer Clinical Trials

PEG-rhG-CSF in Secondary Prevention of Nab-Paclitaxel Combined With S-1 in Advanced Pancreatic Cancer

Start date: August 18, 2020
Phase: N/A
Study type: Interventional

A prospective, open, single-arm clinical study to evaluate the efficacy and safety of jinyouli(PEG-rhG-CSF) in the first-line treatment of advanced pancreatic cancer with nab-paclitaxel combined with S-1.Chemotherapy regimen: (1) chemotherapy: nab-paclitaxel, 260mg/m2, intravenous infusion for 30 minutes, D1, Q3W. S-1, 80-120mg, PO BID, D1-14, Q3W. (2) patients who met the eligibility criteria were given jinyouli injections 24 hours after the end of intravenous infusion of nab-paclitaxel during the treatment period.